0000899243-18-008245.txt : 20180321
0000899243-18-008245.hdr.sgml : 20180321
20180321160031
ACCESSION NUMBER: 0000899243-18-008245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180319
FILED AS OF DATE: 20180321
DATE AS OF CHANGE: 20180321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paggiarino Dario A.
CENTRAL INDEX KEY: 0001574261
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 18704451
MAIL ADDRESS:
STREET 1: 4025 SORRENTO VALLEY BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: pSivida Corp.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-19
0
0001314102
pSivida Corp.
PSDV
0001574261
Paggiarino Dario A.
C/O PSIVIDA CORP.
480 PLEASANT STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Medical Officer
Common stock
2018-03-19
4
A
0
8333
0.00
A
8333
D
On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 4,166 shares representing a previously granted performance stock unit award vested on that date. An additional 4,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
/s/ John Mercer, Attorney-in-Fact
2018-03-21